National Comprehensive Cancer Network Moves Global Headquarters to Plymouth Meeting, PA

Food and Healthcare Press Releases Friday September 28, 2018 08:55
PLYMOUTH MEETING, Pennsylvania--28 Sep--PRNewswire/InfoQuest
  • New location just outside Philadelphia will accommodate expanding operations devoted to improving cancer care worldwide

Today, the National Comprehensive Cancer Network(R) (NCCN(R)) moved into new headquarters in Plymouth Meeting, PA, near Philadelphia. The nonprofit alliance of 27 leading academic cancer centers in the U.S. is moving from Fort Washington, PA. The new location will allow for greater hosting capacity for meetings, guests, and a growing staff.

"This new building is just one example of how NCCN is increasing our ability to address the diverse needs of people with cancer, and the clinicians who provide their care, all over the world," said Robert W. Carlson, MD, CEO, NCCN. "Our expanding capabilities allow us to do more every day to improve the quality, effectiveness, and efficiency of cancer care so that patients can live better lives."

The NCCN Guidelines(R) detail the sequential management decisions and interventions for 97 percent of malignant cancers. In 2018, so far, the organization has added five new NCCN Guidelines(R), four new NCCN Guidelines for Patients(R), four NCCN Harmonized Guidelines for the Caribbean(TM), and is currently developing 17 additional NCCN Harmonized Guidelines for Sub-Saharan Africa(TM). There are now more than 160 international Adaptations and Translations of the NCCN Guidelines(R) available in 11 different languages at NCCN.org or via app.

"International surveys repeatedly show that oncologists worldwide are relying on NCCN Guidelines to stay up-to-date on the best evidence-based cancer care," Dr. Carlson continued. "By growing our global program, we're better able to meet the challenge of making NCCN Guidelines as useful as possible across various settings and circumstances."

About the National Comprehensive Cancer Network

The National Comprehensive Cancer Network(R) (NCCN(R)), a not-for-profit alliance of 27 leading cancer centers devoted to patient care, research, and education, is dedicated to improving the quality, effectiveness, and efficiency of cancer care so that patients can live better lives. Through the leadership and expertise of clinical professionals at NCCN Member Institutions, NCCN develops resources that present valuable information to the numerous stakeholders in the health care delivery system. As the arbiter of high-quality cancer care, NCCN promotes the importance of continuous quality improvement and recognizes the significance of creating clinical practice guidelines appropriate for use by patients, clinicians, and other health care decision-makers. Follow @NCCNnews on Twitter and @National.Comprehensive.Cancer.Network on Facebook.

Media Contact:
Rachel Darwin
267-622-6624
darwin@nccn.org
Logo - https://mma.prnewswire.com/media/441768/NCCN_Logo.jpg

Latest Press Release

Open nursing course to accelerate the safe practice of Peripheral Intravenous Cannula Insertion

"Peripheral Intravenous Cannula Insertion is a very broad term and not likely to be understood by people outside the medical community. In simple terms, it means the provision of saline, medication or blood products through an intravenous device and...

Sirtex Medical reaches milestone 100,000th patient dose delivery of SIR-Spheres(R) Y-90 resin microspheres

- Physicians and employees recognized for their role in this milestone and impact made on patient lives Sirtex Medical, a leading manufacturer of targeted liver cancer therapies, today announced delivery of the 100,000th patient dose of SIR-Spheres(R)...

Most Thai consumers want to improve their diets and are open to healthier product reformulation

According to a new report by Food Industry Asia (FIA) and research firm IGD, almost all consumers in Thailand (99 per cent) are interested in improving their diets and a majority (82 per cent) are happy for products to be reformulated, provided that...

Kemin Launches New Vision and Logo for the Future

Global ingredient manufacturer sets sights on sustainably transforming 80 percent of the world by 2042 Today Kemin Industries, a global ingredient manufacturer, unveiled its new global vision and logo to align the company strategically for 2042 and...

Oral semaglutide demonstrated cardiovascular safety in people with type 2 diabetes and established cardiovascular disease or high cardiovascular risk in PIONEER 6 trial

Novo Nordisk today announced that the PIONEER 6 trial achieved its primary endpoint by demonstrating non-inferiority of major adverse cardiovascular events (MACE) with oral semaglutide compared with placebo, both in addition to standard of care. The...

Related Topics